Adherence to Guideline‐Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: Current guidelines recommend that patients with peripheral arterial disease ( PAD ) cease smoking and be treated with aspirin, statin medications, and angiotensin‐converting enzyme ( ACE ) inhibitors. The combined effects of multiple guideline‐recommended therapies in patients with symptomatic PAD have not been well characterized. Methods and Results: We analyzed a comprehensive database of all patients with claudication or critical limb ischemia ( CLI ) who underwent diagnostic or interventional lower‐extremity angiography between June 1, 2006 and May 1, 2013 at a multidisciplinary vascular center. Baseline demographics, clinical data, and long‐term outcomes were obtained. Inverse probability of treatment propensity weighting was used to determine the 3‐year risk of major adverse cardiovascular or cerebrovascular events ( MACE ; myocardial infarction, stroke, or death) and major adverse limb events ( MALE ; major amputation, thrombolysis, or surgical bypass). Among 739 patients with PAD , 325 (44%) had claudication and 414 (56%) had CLI . Guideline‐recommended therapies at baseline included use of aspirin in 651 (88%), statin medications in 496 (67%), ACE inhibitors in 445 (60%), and smoking abstention in 528 (71%) patients. A total of 237 (32%) patients met all four guideline‐recommended therapies. After adjustment for baseline covariates, patients adhering to all four guideline‐recommended therapies had decreased MACE (hazard ratio [ HR ], 0.64; 95% CI , 0.45 to 0.89; P =0.009), MALE ( HR , 0.55; 95% CI , 0.37 to 0.83; P =0.005), and mortality ( HR , 0.56; 95% CI , 0.38 to 0.82; P =0.003), compared to patients receiving less than four of the recommended therapies. Conclusions: In patients with claudication or CLI , combination treatment with four guideline‐recommended therapies is associated with significant reductions in MACE , MALE , and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 10×
“Data Definitions The ACC/AHA guidelines have indicated aspirin, statins, and smoking abstention as class I recommendations; ACE inhibitors are a class IIa recommendation for treatment of patients with PAD.13,15,27 Each patient’s utilization of these four guideline-recommended therapies (aspirin, statin medications, AC…”
BackgroundInfluentialInter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174526 · Cited by 3,708
Fowkes, F. G. R., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J. O., McDermott, M. M., Norman, P. E., Sampson, U. K., Williams, L. J., Mensah, G. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61249-0 · Cited by 3,508
Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease
Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J., & Browner, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202063260605 · Cited by 2,579 · cited 2×
“PAD has been well established as a prevalent disease associated with significant impairment in quality of life and increased mortality.6–12 A 10-year prospective study by Criqui et al.8 showed that patients with symptomatic PAD have a 10 to 15 times greater risk for cardiovascular-related death, compared to subjects w…”
BackgroundSmith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Cited by
Global Vascular Guidelines on the management of chronic limb-threatening ischemia.
Conte, M. S., Bradbury, A. W., Kolh, P., White, J. V., Dick, F., Fitridge, R., Mills, J. L., Ricco, J.-B., Suresh, K. R., Murad, M. H., et al. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.02.016 · Cited by 2,015
Global vascular guidelines on the management of chronic limb-threatening ischemia
Conte, M. S., Bradbury, A. W., Kolh, P., White, J. V., Dick, F., Fitridge, R., Mills, J. L., Ricco, J.-B., Suresh, K. R., Murad, M. H., et al. (2019) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2019.05.006 · Cited by 1,582
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixido-Tura, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., De Backer, J., Deglise, S., Della Corte, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 993
Criqui, M. H., Matsushita, K., Aboyans, V., Hess, C. N., Hicks, C. W., Kwan, T. W., McDermott, M. M., Misra, S., Ujueta, F., & on behalf of the American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, T. A. V. B. C. O. C. R. A. I. C. O. L. A. C. H. C. O. P. V. D. A. S. C. (2021) · Circulation · doi:10.1161/cir.0000000000001005 · Cited by 809
Nordanstig, J., Behrendt, C.-A., Baumgartner, I., Belch, J., Bäck, M., Fitridge, R., Hinchliffe, R., Lejay, A., Mills, J. L., Rother, U., et al. (2024) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.08.067 · Cited by 515
Armstrong, E. J., Wu, J., Singh, G. D., Dawson, D. L., Pevec, W. C., Amsterdam, E. A., & Laird, J. R. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2014.08.064 · Cited by 202
Self-citationUnderuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease
Berger, J. S., & Ladapo, J. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.064 · Cited by 183
“Although some, but not all, prior studies have reported comparatively higher rates of secondary prevention in patients with PAD, many of these studies focused on selected patients whose use of secondary prevention might be higher than that in the physician office setting assessed here (9,11,22).”
ResultSpence, J. D., Viscoli, C. M., Inzucchi, S. E., Dearborn-Tomazos, J., Ford, G. A., Gorman, M., Furie, K. L., Lovejoy, A. M., Young, L. H., Kernan, W. N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0079 · Cited by 109
Hua, S., Isasi, C. R., Kizer, J. R., Matsushita, K., Allison, M. A., Tarraf, W., Qi, Q., Ponce, S. G., Daviglus, M., & Kaplan, R. C. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015451 · Cited by 28
El Morr, C., AlHamzah, M., Ng, P., Purewal, A., & Al-Omran, M. (2017) · Vascular · doi:10.1177/1708538116689355 · Cited by 23
Schleyer, T., Hui, S., Wang, J., Zhang, Z., Knapp, K., Baker, J., Chase, M., Boggs, R., & Simpson, R. J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.5.544 · Cited by 19
Smolderen, K. G., Ameli, O., Chaisson, C. E., Heath, K., & Mena-Hurtado, C. (2022) · AJPM Focus · doi:10.1016/j.focus.2022.100016 · Cited by 11
“Preventive strategies should entail pathways that offer linkage to care to ensure access to guideline-recommended therapy and support to make lifestyle modi fi cations, 10 especially among individuals who previously did not have another diagnosis of cardiovascular disease.”
BackgroundMethodLampridou, S., Rawasdheh, M., Saghdaoui, L. B., Wells, M., & Davies, A. H. (2024) · JVS-Vascular Insights · doi:10.1016/j.jvsvi.2024.100074 · Cited by 7
Metadata
- Authors
- Armstrong, E. J., Chen, D. C., Westin, G. G., Singh, S., McCoach, C. E., Bang, H., Yeo, K., Anderson, D., Amsterdam, E. A., & Laird, J. R.
- Venue
- Journal of the American Heart Association
- Published
- 2014-03-24
- Volume
- 3
- Issue
- 2
- Pages
- e000697-e000697
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2169041305
- Cited by
- 247
- References
- 17
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.